• Elanco Animal Health posted Q1 2026 net income of $57 million, down 15%, as revenue climbed 15% to $1.37 billion.
• Adjusted EBITDA rose 21% to $334 million, lifting adjusted EBITDA margin by 1.4 percentage points to 24.5%.
• Pet Health revenue increased 12% to $710 million, while Farm Animal revenue jumped 18% to $642 million.
• Credelio Quattro accelerated U.S. clinic share gains and expanded distribution, while Zenrelia reached trailing four-quarter blockbuster status with more than 2 million dogs treated.
• Full-year revenue outlook was raised to $5.01 billion-$5.09 billion, with adjusted EPS guidance lifted to $1.03-$1.09 and year-end net leverage ratio target improved to 3.0x-3.2x adjusted EBITDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605060627PR_NEWS_USPR_____DE52040) on May 06, 2026, and is solely responsible for the information contained therein.